drugset
drugset / Trial / NCT07624214

Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors

NCT07624214 ↗

Phase 1 Not yet recruiting 198 enrolled Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the safety and tolerability of of LT-010391 as monotherapy in participants with KRAS G12D mutant advanced solid tumors

Timeline

Start
2026-07
Primary completion
2028-04
Completion
2029-04

Drugs

EvaluationDrugModalityDoseRoute
Subject LT-010391 Unknown — Oral

Indications

colorectal cancer non-small cell lung carcinoma pancreatic ductal adenocarcinoma